Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind multi-dose placebo-controlled trial of TTYP01 in children and adolescents with autism spectrum disorder
CTR20244760Phase 2Active
- Sponsor
- Suzhou Aozong Biotechnology
- Start
- Jan 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of FAB122 in Autism Spectrum Disorder (ASD), sponsored by Suzhou Aozong Biotechnology. Started Jan 2025; status: active.
02
Drugs
FAB122
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on CTR20244760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244760.